Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.

doi:10.1002/pros.21207

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.

The Prostate - 1 Nov 2010

Agalliu Ilir, Leanza Suzanne M, Smith Lorie, Trent Jeffrey M, Carpten John D, Bailey-Wilson Joan E, Burk Robert D

Abstract excerpt

BACKGROUND: Prostate cancer is a genetically complex disease with locus and disease heterogeneity. The RNASEL gene and HPCX locus have been implicated in hereditary prostate cancer; however, their contributions to sporadic forms of this malignancy remain uncertain. METHODS: Associations of prostate cancer with two variants in the RNASEL gene (a founder mutation, 471delAAAG, and a non-synonymous SNP, rs486907),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Chi-Square Distribution

Share to DNA, Neoplasm

Share to Endoribonucleases

Share to Jews

Share to Microsatellite Repeats

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20564318
DOI: 10.1002/pros.21207
PMCID: PMC3404133

Genes

RNASEL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.PMID 20564318Read ↗

Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate CancerSemantic proximity Read ↗

A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.Semantic proximity Read ↗

Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.Semantic proximity Read ↗

RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.Semantic proximity Read ↗

Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer.Semantic proximity Read ↗

Perspective: prostate cancer susceptibility genes.Semantic proximity Read ↗

Evidence from 40 Studies that 2 Common Single-Nucleotide Polymorphisms (SNPs) of RNASEL Gene Affect Prostate Cancer Susceptibility: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Compliant Meta-Analysis.Semantic proximity Read ↗

Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.Semantic proximity Read ↗

Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.Semantic proximity Read ↗

Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.Semantic proximity Read ↗

Involvement of the RNAse L gene in prostate cancer.Semantic proximity Read ↗

A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.